POPA ReconUneven Frontiers - How AI will transform biopharma and why the sequence of change matters
Uneven Frontiers - How AI will transform biopharma and why the sequence of change matters AI is rapidly accelerating early-stage drug discovery and creating an abundance of candidate molecules, but human clinical trials remain the industry's ultimate bottleneck Because of this uneven progress, long-term value will belong to biopharma companies built around superior clinical development and asset selection rather than discovery models alone https://www.a16z.news/p/uneven-frontiers
The excerpt is quoted from a public Telegram channel, which owns its text.